Physician profile
Alan Gamsey
NPI 1043295348
$14,075.72
in general payments reported to CMS, 2019-2025
43 companies · $1,718 in 2025
The $1,718 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,754 · 2020: $1,235 · 2021: $1,812 · 2022: $2,527 · 2023: $2,303 · 2024: $2,727 · 2025: $1,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,603 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,602.93 |
| Education | $145.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,680.81 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,757.94 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,412.68 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,126.72 | 2019-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $977.16 | 2019-2025 | |
| Qol Medical, LLC | $662.15 | 2019-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $591.45 | 2019-2025 | Injectafer |
| Celgene Corporation | $553.58 | 2021-2024 | Zeposia |
| Pfizer INC. | $366.21 | 2019-2025 | |
| Celltrion USA INC. | $277.79 | 2024-2025 | Zymfentra, Vegzelma |
| Regeneron Healthcare Solutions, INC. | $272.76 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $238.00 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $229.74 | 2019-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $194.15 | 2020-2023 | |
| Ironwood Pharmaceuticals, INC | $192.23 | 2020-2024 | Linzess |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Gamsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.